An FDA adcomm that met Wednesday to vote on GlaxoSmithKline’s daprodustat for adult patients with anemia due to chronic kidney disease (CKD) produced mixed results.
Tag Archive for: hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI)
The FDA’s Cardiovascular and Renal Drugs Advisory Committee (RDAC) will meet Wednesday to review GlaxoSmithKline’s daprodustat, intended to treat anemia due to chronic kidney disease (CKD) in adults.